JMP reiterates Market Outperform rating on Larimar stock despite safety concerns

Larimar Therapeutics (LRMR) experienced a significant stock decline of 34% on Monday and 24% over the past week, driven by investor concerns regarding anaphylaxis cases linked to its Friedreich’s Ataxia drug, nomlabofusp, which reduced its enterprise value to under $90 million. However, JMP Securities reiterated its Market Outperform rating and $18 price target, emphasizing that the anaphylaxis rates (11-18%) are relatively low and comparable to other approved drugs, the FDA has approved an updated dosing protocol and allowed dosing in young children, and the company maintains a strong financial position. Other analysts also maintain positive ratings, citing robust efficacy data and a potential Q2 2026 accelerated approval filing, suggesting that despite recent volatility, the drug's long-term potential and approvability remain strong.

Analysis

Larimar Therapeutics (LRMR) has experienced a significant valuation reset, with its stock declining 34% in a single day and its enterprise value falling below $90 million due to investor concerns over the safety profile of its Friedreich’s Ataxia drug, nomlabofusp. Specifically, seven cases of anaphylaxis were reported in its open-label study, representing an 11% overall incidence rate and 18% for patients in that specific trial. Despite this, several analysts maintain Buy/Outperform ratings, viewing the sell-off as an overreaction. JMP Securities, for instance, argues the anaphylaxis rate is not a barrier to approval, drawing a parallel to the approved drug Palynziq, which has a 10% incidence rate and a Black Box warning. Crucially, the FDA seems to view the risk as manageable, having approved an updated dosing protocol to mitigate events and allowing the trial to include children as young as two. This regulatory signal, combined with strong efficacy data showing frataxin levels exceeding 50% of the median in healthy volunteers, supports the drug's potential. The company's financial position is robust, with more cash than debt and a current ratio of 5.46, providing a solid runway to its anticipated Q2 2026 accelerated approval filing. The wide dispersion of analyst price targets, from $7.00 to $26.00, underscores the binary risk profile but also the significant upside potential if safety concerns are successfully managed.

Key Decisions for Investors

• Investors should view the 34% stock price decline as a potential entry point, contingent on an assessment that the anaphylaxis risk is manageable and has been overly discounted by the market.
• The key forward-looking indicator is the performance of the updated dosing protocol; data demonstrating a reduction in anaphylaxis events will be a primary de-risking catalyst for the stock.
• Given the projected FDA filing date in the second quarter of 2026, this is a long-term, high-risk, high-reward opportunity suitable for investors with a multi-year horizon.
• The company's strong balance sheet, with more cash than debt, should be monitored to ensure it provides a sufficient financial runway to reach key regulatory milestones without significant shareholder dilution.